Allopurinol and Endothelial Function in Diabetic CAD Patients

• Status: Unknown status
• Trial end date: 2018-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized trial assessing the impact of allopurinol on endothelial function in optimally treated diabetic patients with coronary artery disease. After initial screening, subjects were randomized to receive either optimal medical therapy (OMT) + allopurinol or OMT alone for 8 weeks. The dose of allopurinol was 300 mg for 4 weeks and 600 mg for 4 weeks with a 4-weekly check on hematology and biochemistry

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Tunis El Manar
• Treatments: Allopurinol

Criteria

Inclusion Criteria:

• Diabetes type 2

• Known coronary artery disease with previous percutaneous coronary intervention and optimal medical therapy for at least one month

Exclusion Criteria:

• Pregnant or breast- feeding women

• creatinine clearance <60ml/min

• Known history of gout disease or ongoing treatment with allopurinol

• Allergy to allopurinol

• Inability to provide informed consent